Poly Medicure Limited (POLYMED) AI Stock Analysis

• Market Cap: ₹180.21B
• Dividend Yield: 0.19%
• Average Volume (3M): 8.86K
• Price to Earnings (P/E): 49.8
• Beta (1Y): 1.00
• Revenue Growth: 12.46%
• EPS Growth: 16.66%
• Country: IN
• Employees: 6,300
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 9.10
• Shares Outstanding: 101,359,490
• 10 Day Avg. Volume: 7,511
• 30 Day Avg. Volume: 8,860
• PEG Ratio: 2.36
• Price to Book (P/B): 7.72
• Price to Sales (P/S): 12.79
• P/FCF Ratio: -235.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 72 Outperform
• Price Target: ₹2,294.00 ▲(33.10% Upside)

Poly Medicure Limited's strong financial performance and positive technical indicators are offset by a high valuation, suggesting potential overvaluation. The company's robust financial health and market momentum are significant strengths, but the high P/E ratio and low dividend yield are notable risks.

Positive Factors

Revenue Growth

Consistent revenue growth indicates robust market demand and effective sales strategies, enhancing long-term business sustainability.

Market Position

Strong market position in the healthcare sector with innovative products supports competitive advantage and long-term growth potential.

Balance Sheet Health

A healthy balance sheet with low leverage enhances financial stability and provides flexibility for future investments and growth.

Negative Factors

Free Cash Flow

Negative free cash flow can limit the company's ability to fund operations and growth initiatives, posing a risk if not managed effectively.

Capital Efficiency

Rapid asset growth without corresponding efficiency improvements may lead to resource misallocation, affecting profitability.

EBIT Margin Variability

Fluctuating EBIT margins indicate potential instability in operational efficiency, which could impact long-term profitability.

Poly Medicure Limited Business Overview & Revenue Model

Company Description

Poly Medicure Limited manufactures and sells medical devices. It offers infusion devices, such as I.V. cannulas, mid line catheters, arterial cannula, three way stop cocks, I.V. infusion sets, manifolds, safety winged infusion sets, T-type extension sets, stylet/mandrin with luer locks, vial access spikes, measured volume fluid administration sets, extension lines, central venous catheters, CVP manometers, needle free connectors, pre filled syringes, vascular accesses, and blood administration sets. The company also provides nasogastric and infant feeding tubes, gastro-duodenal feeding tubes, and umbilical catheters; urine collection bags, foley balloon catheters, irrigation sets, urine drainage catheters, and urine collection bags with measured volume meters; and endotracheal tubes, tracheostomy tubes, mucus extractors, ventilator circuits, bain circuits, catheter mounts, spinal needles, HME filters, and laryngeal mask airways. In addition, it offers oncology products; endo bronchial suction catheters, oxygen catheters, respiratory exercisers, nasal oxygen cannulas, oro-pharyngeal airways, variable concentration masks, oxygen mask with reservoirs, fixed concentration masks, and aerosol therapy masks; and dialyzers, blood lines, dialysis systems, fistula needles, haemodialysis catheters, and peritoneal dialysis and transfusion sets. Further, it provides closed wound suction units, under water seal drainage systems, high pressure vacuum bottles, yankauer suction sets, and thoracic drainage catheters; blood collection tubes, safety blood collection sets, blood collection needles, erythrocyte sedimentation rate pipettes, and luer adaptors; blood bag systems; face protective shields, polymasks, and viral transport medium kits; and insulin syringes, sputum collectors, dry brushes, umbilical cord clamps, luer locks, cannula fixators, injection stoppers, luer lock injection sites, and universal caps. The company was incorporated in 1995 and is based in New Delhi, India.

How the Company Makes Money

Poly Medicure Limited generates revenue through the sale of its medical devices and consumables, which are distributed to hospitals, clinics, and healthcare providers both domestically and internationally. The company's revenue model is primarily based on direct sales and distribution agreements. Key revenue streams include the sale of intravenous sets, catheters, and other disposable medical products. POLYMED also engages in strategic partnerships with healthcare institutions and distributors, which help expand its market reach and enhance brand visibility. The company's focus on research and development fosters innovation, enabling it to introduce new products that meet evolving healthcare needs, thereby driving additional revenue growth.

Poly Medicure Limited Financial Statement Overview

Summary

Poly Medicure Limited exhibits strong financial health with consistent revenue growth and solid profitability margins. The balance sheet reflects financial stability with low leverage and increasing equity. However, negative free cash flow due to high capital expenditures highlights the need for careful capital management.

Income Statement

Poly Medicure Limited's income statement reveals impressive revenue growth, with a consistent upward trajectory from 2020 to 2025. The gross profit margin remains strong, reflecting efficient cost management and a solid market position. The net profit margin has also improved, indicating enhanced profitability. However, the EBIT margin shows some fluctuation, suggesting variability in operational efficiency.

Balance Sheet

The balance sheet of Poly Medicure Limited indicates solid financial stability, with a low debt-to-equity ratio that underscores prudent financial management. The company has consistently increased its stockholders' equity, supporting a strong equity ratio. However, despite these strengths, the company's asset base has grown significantly, which could suggest potential capital inefficiencies.

Cash Flow

Poly Medicure Limited's cash flow statements demonstrate a robust operating cash flow, which is a positive indicator of the company's ability to generate cash from its core operations. However, the free cash flow has been negative in recent years due to high capital expenditures, which could pose a risk if not managed carefully. The cash flow from investing activities suggests significant reinvestment into the business, which may drive future growth.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	16.88B	16.70B	13.76B	11.15B	9.23B	7.86B
Gross Profit	11.30B	11.11B	8.89B	7.06B	5.72B	5.23B
EBITDA	4.47B	4.52B	3.58B	2.68B	2.12B	2.13B
Net Income	3.58B	3.39B	2.58B	1.79B	1.47B	1.36B
Balance Sheet
Total Assets	0.00	31.92B	18.59B	15.77B	13.77B	12.24B
Cash, Cash Equivalents and Short-Term Investments	12.08B	12.08B	2.86B	3.01B	3.52B	3.74B
Total Debt	0.00	1.80B	1.74B	1.49B	1.27B	1.37B
Total Liabilities	-27.66B	4.27B	3.89B	3.36B	2.89B	2.58B
Stockholders Equity	27.66B	27.66B	14.70B	12.42B	10.87B	9.66B
Cash Flow
Free Cash Flow	0.00	-906.06M	-109.34M	-484.49M	-321.05M	236.01M
Operating Cash Flow	0.00	2.40B	2.66B	1.91B	1.23B	1.19B
Investing Cash Flow	0.00	-11.94B	-2.41B	-1.79B	-853.32M	-4.36B
Financing Cash Flow	0.00	9.51B	-201.53M	-125.05M	-353.38M	3.17B

Poly Medicure Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1723.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:POLYMED, the sentiment is Negative. The current price of 1723.55 is below the 20-day moving average (MA) of 1789.96, below the 50-day MA of 1870.84, and below the 200-day MA of 2076.78, indicating a bearish trend. The MACD of -29.76 indicates Negative momentum. The RSI at 45.54 is Neutral, neither overbought nor oversold. The STOCH value of 66.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:POLYMED.

Poly Medicure Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
POLYMED	72 Outperform	₹180.21B	49.77	―	0.19%	12.46%	16.66%
ERIS	70 Outperform	₹205.02B	49.31	―	0.47%	20.02%	19.17%
GLAND	63 Neutral	₹276.91B	35.03	―	1.07%	-1.51%	14.27%
GLAXO	63 Neutral	₹402.25B	42.11	―	2.16%	4.17%	41.51%
APLLTD	60 Neutral	₹157.23B	24.78	―	1.28%	11.42%	-1.91%
GLENMARK	53 Neutral	₹566.35B	56.08	―	0.24%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Poly Medicure Limited Corporate Events

Poly Medicure Schedules Investor Meetings for November 2025

Poly Medicure Limited announced the schedule for upcoming one-on-one meetings with investors and analysts, set to take place virtually on November 25 and 26, 2025. These meetings, which are part of the company’s regulatory obligations, aim to engage stakeholders without sharing any unpublished price-sensitive information, reflecting the company’s commitment to transparency and investor relations.